Payment overview · 2025
General Payments
$288.19
4 reported records · 4 companies
Healthcare provider profile · identity verified
Mohammad Saleh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GRAND RAPIDS, MI · NPI 1992751739
Verified facts
What the public records show
CMS Open Payments records show Mohammad Saleh, MD received $288.19 in general payments during 2025 across 4 reported records.
Sequel Med Tech, LLC accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $123.52 | 42.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$115.98 | 40.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $29.22 | 10.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.47 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.19 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $123.52 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOBLATE GEMINI Normalized: cardioblate gemini |
Device | Medtronic, Inc. | $115.98 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $19.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 617 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 124 |
| Losartan Potassium | Losartan Potassium | 413 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 111 |
| Omeprazole | Omeprazole | 329 | 104 |
| Trazodone Hcl | Trazodone Hcl | 317 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 99 |
| Lisinopril | Lisinopril | 281 | 77 |
| Metformin Hcl | Metformin Hcl | 262 | 83 |
| Duloxetine Hcl | Duloxetine Hcl | 243 | 79 |
| Gabapentin | Gabapentin | 235 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 68 |
| Meloxicam | Meloxicam | 184 | 71 |
| Prednisone | Prednisone | 166 | 107 |
| Metformin Hcl Er | Metformin Hcl | 160 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 53 |
| Finasteride | Finasteride | 142 | 40 |
| Atenolol | Atenolol | 139 | 38 |
| Trulicity | Dulaglutide | 138 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 42 |
| Montelukast Sodium | Montelukast Sodium | 128 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 43 |
| Simvastatin | Simvastatin | 117 | 35 |
| Farxiga | Dapagliflozin Propanediol | 111 | 32 |
| Furosemide | Furosemide | 110 | 45 |
| Carvedilol | Carvedilol | 108 | 36 |
| Eliquis | Apixaban | 107 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 34 |
| Famotidine | Famotidine | 102 | 32 |
| Tramadol Hcl | Tramadol Hcl | 99 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 95 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 86 | 40 |
| Mounjaro | Tirzepatide | 86 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 46 |
| Doxazosin Mesylate | Doxazosin Mesylate | 84 | 26 |
| Alprazolam | Alprazolam | 82 | 22 |
| Allopurinol | Allopurinol | 79 | 25 |
| Mirtazapine | Mirtazapine | 78 | 24 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 69 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 18 |
| Bupropion Xl | Bupropion Hcl | 67 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 20 |
| Ozempic | Semaglutide | 65 | 12 |
| Jardiance | Empagliflozin | 64 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 20 |
| Lovastatin | Lovastatin | 61 | 17 |
| Buspirone Hcl | Buspirone Hcl | 60 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 19 |
| Glimepiride | Glimepiride | 59 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 13 |
| Ezetimibe | Ezetimibe | 52 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 52 | 15 |
| Hydrocortisone | Hydrocortisone | 49 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 14 |
| Xarelto | Rivaroxaban | 47 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 11 |
| Lactulose | Lactulose | 44 | 25 |
| Spironolactone | Spironolactone | 44 | 18 |
| Cephalexin | Cephalexin | 43 | 28 |
| Donepezil Hcl | Donepezil Hcl | 43 | 13 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 23 |
| Ketoconazole | Ketoconazole | 41 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 12 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 29 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 12 |
| Methocarbamol | Methocarbamol | 27 | 11 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Nystatin | Nystatin | 19 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Theophylline | Theophylline Anhydrous | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $288.19 · 4 records | Sequel Med Tech, LLC | CARDIOBLATE GEMINI, CRENESSITY, TWIIST, UNITHROID | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error